# Safety and Pharmacokinetics of LPX-TI641 in Atopic Dermatitis and Psoriasis

> **NCT06982352** · PHASE1 · RECRUITING · sponsor: **LAPIX Therapeutics Inc.** · enrollment: 48 (estimated)

## Conditions studied

- Atopic Dermatitis (AD)
- Psoriasis (PsO)

## Interventions

- **DRUG:** LPX-TI641
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06982352
- **Lead sponsor:** LAPIX Therapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-15
- **Primary completion:** 2026-01-15
- **Final completion:** 2026-04-15
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2025-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06982352

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06982352, "Safety and Pharmacokinetics of LPX-TI641 in Atopic Dermatitis and Psoriasis". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT06982352. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*